Synopsys reports its quarterly results today with the street leaning bullish, options hedges unwound, and the stock sitting at its best level in months.
The options market has shifted decisively toward calls. The put/call ratio landed at 0.90 on Tuesday — more than one standard deviation below its 20-day average of 1.04. That is a meaningful rotation: through early May the PCR briefly touched its 52-week high of 1.21, with traders piling on protection. That defensive posture has been almost entirely dismantled heading into the print. Borrow conditions mirror this lack of anxiety. Short interest has fallen roughly 9.7% over the past month to 2.4% of free float — a low and declining number. The cost to borrow is just 0.46%, and availability in the lending pool is effectively unlimited, with available shares dwarfing what is currently borrowed. There is no squeeze dynamic, no crowded short, nothing to unwind.
Analyst moves this week reinforce the constructive read. Rosenblatt raised its target to $575 from $530 yesterday while holding its Buy rating — a direct response to what management said. Citigroup moved first earlier in the month, lifting to $600. Wells Fargo raised its Equal-Weight target to $505 from $450. The direction of travel is clear: firms that already believed in the story got more confident, while the most notable holdout — Morgan Stanley, which downgraded to Equal-Weight in late February and cut to $480 — has not yet moved back. The consensus mean target is $545. Shares closed at $534.56, so the stock is trading just inside that level, meaning the average analyst sees only modest additional upside from here unless the print drives another round of upgrades.
The bull case rests on Synopsys's position at the centre of AI-driven chip complexity. Physical AI and leading-edge node design require more EDA cycles, and Synopsys is one of only two vendors with the full stack to capture that demand. Bears point to customer concentration risk at Intel, mounting competition from in-house design efforts, and lingering headwinds from China export controls that have crimped the IP business. The valuation is not cheap — the stock trades at roughly 34.5x trailing earnings and 25.2x EV/EBITDA — but both multiples have expanded over the past month alongside the rally. Factor scores are broadly neutral: EPS forward momentum ranks in the 64th percentile, the short score ranks 64th, and EPS surprise at the 21st percentile flags that beats have not been the consistent pattern recently.
Earnings history adds a note of caution to the constructive positioning. The last print in April produced a modest 2.5% one-day gain, but the two releases before that — March and February — both saw the stock fall between 3% and 4.7% on the day and continue lower into the following week. The five-day move after the February print was -2.2%; after March it was -1.1%. Three of the last four earnings events have seen the stock close lower within a week. That history sits uneasily against the bullish options setup, which is one reason the PCR reset is worth watching closely rather than simply treating as a green light.
Closest peer Cadence Design Systems gained 10.3% on the week and 2.2% on Tuesday — the EDA duopoly has moved largely in lockstep into the reporting window. The degree to which Synopsys's guidance on AI-linked design tool demand either matches or diverges from what CDNS has recently signalled will be the key read for whether today's constructive positioning proves well-placed or premature.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
